Cargando…
Efanesoctocog Alfa: First Approval
Efanesoctocog alfa (ALTUVIIIO(TM); [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl]), a von Willebrand factor (VWF) independent, recombinant DNA-derived Factor VIII (FVIII) concentrate, has been developed by Bioverativ Therapeutics, Inc (a Sanofi company) and Swedish Orphan Bio...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10238336/ https://www.ncbi.nlm.nih.gov/pubmed/37022666 http://dx.doi.org/10.1007/s40265-023-01866-9 |